



Vaccines against Enteric Bacterial Pathogens in Poultry

Guest Editors:

Dr. Khaled Abdelaziz

Department of Animal and
Veterinary Sciences, Clemson
University, Clemson, SC 29634,
USA

Dr. Ahmed Ali

Poultry Diseases Department,
Faculty of Veterinary Medicine,
Beni-Suef University, Beni-Suef
62511, Egypt

Deadline for manuscript
submissions:

31 October 2024

Message from the Guest Editors

As the poultry industry transitions into the "no antibiotic era," it becomes critically imperative to advance the development of vaccines able to target emerging bacterial diseases that pose a significant economic threat to the poultry industry, with necrotic enteritis caused by *C. perfringens* being a notable example. Additionally, there is a need to control foodborne bacterial pathogens that pose threats to public health, such as *Salmonella* spp., *Campylobacter* spp., *E. coli*, and *L. monocytogenes*.

This Special Issue is dedicated to showcasing recent scientific and technical advancements in vaccines that are designed to combat enteric bacterial pathogens in poultry. We extend an invitation for contributions in the form of original research or review articles, focusing on innovative vaccination strategies. This includes exploring the use of recombinant technology and nanotechnology in vaccine development and delivery, as well as investigating new immunomodulators and adjuvants like Toll-like receptor ligands, cytokines, nanoparticles, probiotics, and other novel agents to enhance vaccine immunogenicity and protective efficacy against the aforementioned bacterial pathogens.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com